analysis

2:28
Midostaurin: the first drug to receive approval for AML since 2000
Arnold Ganser
1:38
Challenges with the identification of ALL subtypes
Charles Mullighan
2:24
Current understandings of ALL approaches
Charles Mullighan
1:19
Myeloma XI trial: impact of MRD on treatment response in MM
Graham Jackson
1:34
Multiple myeloma highlights at ASH 2017
Graham Jackson
2:19
ASH 2017: CLL combination therapy highlights
Arnon Kater
3:12
Results of the MURANO study for CLL
Arnon Kater
1:18
ASH 2017: combination therapy for CLL highlights
Barbara Eichhorst
1:10
Impacts of the MURANO study for future CLL treatment
Barbara Eichhorst
2:38
“Sequential triple-T” therapy for CLL
Barbara Eichhorst
2:19
Bendamustine plus rituximab vs. standard therapy for advanced CLL
Barbara Eichhorst
1:48
Novel CLL therapy highlights from ASH 2017
Anthony Mato
1:13
Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies
Anthony Mato
3:21
Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib
Anthony Mato
3:36
Retrospective multicenter analysis of venetoclax-treated CLL patients
Anthony Mato
1:38
Front-line use of ibrutinib for CLL in a real-world setting
Anthony Mato
The content of VJHemOnc is intended for healthcare professionals